ATE448778T1 - Muscarin-agonisten zur behandlung von impulskontrollstörungen - Google Patents

Muscarin-agonisten zur behandlung von impulskontrollstörungen

Info

Publication number
ATE448778T1
ATE448778T1 AT07728391T AT07728391T ATE448778T1 AT E448778 T1 ATE448778 T1 AT E448778T1 AT 07728391 T AT07728391 T AT 07728391T AT 07728391 T AT07728391 T AT 07728391T AT E448778 T1 ATE448778 T1 AT E448778T1
Authority
AT
Austria
Prior art keywords
impulse control
control disorders
disorder
agonists
treatment
Prior art date
Application number
AT07728391T
Other languages
English (en)
Inventor
Bruin Natasja M W J De
Drimmelen Marlies L Van
Arnoldus H J Herremans
Martinus Th M Tulp
Cornelis G Kruse
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of ATE448778T1 publication Critical patent/ATE448778T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT07728391T 2006-05-04 2007-04-23 Muscarin-agonisten zur behandlung von impulskontrollstörungen ATE448778T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79735506P 2006-05-04 2006-05-04
EP06113476 2006-05-04
PCT/EP2007/053934 WO2007128674A2 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders

Publications (1)

Publication Number Publication Date
ATE448778T1 true ATE448778T1 (de) 2009-12-15

Family

ID=38544084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07728391T ATE448778T1 (de) 2006-05-04 2007-04-23 Muscarin-agonisten zur behandlung von impulskontrollstörungen

Country Status (12)

Country Link
EP (1) EP2023909B1 (de)
JP (1) JP2010501471A (de)
KR (1) KR20090013815A (de)
AT (1) ATE448778T1 (de)
AU (1) AU2007247231B2 (de)
CA (1) CA2649917A1 (de)
DE (1) DE602007003348D1 (de)
EA (1) EA014915B1 (de)
ES (1) ES2336275T3 (de)
IL (1) IL194778A0 (de)
PL (1) PL2023909T3 (de)
WO (1) WO2007128674A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294835A1 (en) * 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
BR112021005802B1 (pt) 2018-09-28 2022-02-15 Karuna Therapeutics, Inc Composição farmacêutica oral

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
WO2002067931A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
WO2006017614A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Also Published As

Publication number Publication date
EA200870498A1 (ru) 2009-04-28
EP2023909B1 (de) 2009-11-18
WO2007128674A2 (en) 2007-11-15
DE602007003348D1 (de) 2009-12-31
JP2010501471A (ja) 2010-01-21
PL2023909T3 (pl) 2010-04-30
IL194778A0 (en) 2009-08-03
AU2007247231A1 (en) 2007-11-15
CA2649917A1 (en) 2007-11-15
AU2007247231B2 (en) 2012-05-31
EP2023909A2 (de) 2009-02-18
WO2007128674A3 (en) 2008-04-03
KR20090013815A (ko) 2009-02-05
ES2336275T3 (es) 2010-04-09
EA014915B1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
ATE448778T1 (de) Muscarin-agonisten zur behandlung von impulskontrollstörungen
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
IL197118A0 (en) Ultrasonic treatment of glaucoma
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
EP2397159A3 (de) Kombination von Morphinan-Verbindungen und Antidepressiva zur Behandlung von hartnäckigen und chronischen Schmerzen
WO2008036678A3 (en) Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
FI20041152L (fi) Kemiallisen massan ksylanaasikäsittely
FR2927330B1 (fr) Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
EP1919480A4 (de) Hedgehog-weg-antagonisten zur behandlung von krankheiten
EP2364705A3 (de) Modulatoren von muskarinischen Rezeptoren
TN2009000014A1 (en) Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same
DE602004025508D1 (de) Modulatoren von peripheren 5-ht-rezeptoren
RU2011103475A (ru) Новая возможность борьбы с гиардиазом
EP1749000A4 (de) Bicyclische substituierte triazole als ppar-modulatoren und verfahren zu deren herstellung
DE60127712D1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
AR060722A1 (es) Agonistas muscarinicos para tratar trastornos de control de impulsos. uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties